{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:16:59Z","timestamp":1783693019374,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"CHRU de Tours"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40262-025-01549-6","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T14:47:21Z","timestamp":1755182841000},"page":"1639-1654","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunoglobulin G Receptors (Fc\u03b3R), in Addition to Target-Antigen and Neonatal Fc Receptor (FcRn), Influence Rituximab Pharmacokinetics"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4020-4545","authenticated-orcid":false,"given":"David","family":"Ternant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Le Tilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Desvignes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Bensalem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Mulleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Bejan-Angoulvant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Gouilleux-Gruart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Paintaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"1549_CR1","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s40262-020-00874-2","volume":"59","author":"A Bensalem","year":"2021","unstructured":"Bensalem A, Ternant D. Pharmacokinetic variability of therapeutic antibodies in humans: a comprehensive review of population pharmacokinetic modeling publications. Clin Pharmacokinet. 2021;59:857\u201374.","journal-title":"Clin Pharmacokinet"},{"key":"1549_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40262-019-00816-7","volume":"59","author":"A Petitcollin","year":"2021","unstructured":"Petitcollin A, Bensalem A, Verdier MC, et al. Modelling of the time-varying pharmacokinetics of therapeutic monoclonal antibodies: a literature review. Clin Pharmacokinet. 2021;59:37\u201349.","journal-title":"Clin Pharmacokinet"},{"key":"1549_CR3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1023\/A:1014414520282","volume":"28","author":"DE Mager","year":"2001","unstructured":"Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28:507\u201332.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1549_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40262-018-0680-3","volume":"58","author":"D Ternant","year":"2019","unstructured":"Ternant D, Azzopardi N, Raoul W, et al. Influence of antigen mass on the pharmacokinetics of therapeutic antibodies in humans. Clin Pharmacokinet. 2019;58:169\u201387.","journal-title":"Clin Pharmacokinet"},{"key":"1549_CR5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40262-021-01081-3","volume":"61","author":"A Bensalem","year":"2022","unstructured":"Bensalem A, Cartron G, Specks U, et al. The influence of underlying disease on rituximab pharmacokinetics may be explained by target-mediated drug disposition. Clin Pharmacokinet. 2022;61:423\u201337.","journal-title":"Clin Pharmacokinet"},{"key":"1549_CR6","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s40262-019-00826-5","volume":"59","author":"A Bensalem","year":"2021","unstructured":"Bensalem A, Mulleman D, Paintaud G, et al. Non-linear rituximab pharmacokinetics and complex relationship between rituximab concentrations and anti-neutrophil cytoplasmic antibodies (ANCA) in ANCA-associated vasculitis: the RAVE trial revisited. Clin Pharmacokinet. 2021;59:519\u201330.","journal-title":"Clin Pharmacokinet"},{"key":"1549_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s002770050396","volume":"76","author":"JE Gessner","year":"1998","unstructured":"Gessner JE, Heiken H, Tamm A, et al. The IgG Fc receptor family. Ann Hematol. 1998;76:231\u201348. https:\/\/doi.org\/10.1007\/s002770050396.","journal-title":"Ann Hematol"},{"key":"1549_CR8","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","volume":"113","author":"P Bruhns","year":"2009","unstructured":"Bruhns P, Iannascoli B, England P, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113:3716\u201325. https:\/\/doi.org\/10.1182\/blood-2008-09-179754.","journal-title":"Blood"},{"key":"1549_CR9","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.3390\/ijms22116051","volume":"22","author":"G Thibault","year":"2021","unstructured":"Thibault G, Paintaud G, Sung HC, et al. Association of IgG1 antibody clearance with Fc\u03b3RIIA polymorphism and platelet count in infliximab-treated patients. Int J Mol Sci. 2021;22:6051. https:\/\/doi.org\/10.3390\/ijms22116051.","journal-title":"Int J Mol Sci"},{"key":"1549_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1385\/IR:25:2:097","volume":"25","author":"V Ghetie","year":"2002","unstructured":"Ghetie V, Ward ES. Transcytosis and catabolism of antibody. Immunol Res. 2002;25:97\u2013113. https:\/\/doi.org\/10.1385\/IR:25:2:097.","journal-title":"Immunol Res"},{"key":"1549_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/BF02786322","volume":"16","author":"RP Junghans","year":"1997","unstructured":"Junghans RP. Finally! The Brambell receptor (FcRB) Mediator of transmission of immunity and protection from catabolism for IgG. Immunol Res. 1997;16:29\u201357.","journal-title":"Immunol Res"},{"key":"1549_CR12","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1158\/1078-0432.CCR-21-3140","volume":"28","author":"M Autio","year":"2022","unstructured":"Autio M, Leivonen SK, Br\u00fcck O, et al. Clinical impact of immune cells and their spatial interactions in diffuse large B-cell lymphoma microenvironment. Clin Cancer Res. 2022;28:781\u201392.","journal-title":"Clin Cancer Res"},{"key":"1549_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.5045\/br.2022.2021145","volume":"57","author":"AM Greenbaum","year":"2023","unstructured":"Greenbaum AM, Fromm JR, Gopal AK, et al. Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8(+) T-cells despite immune checkpoint signaling. Blood. 2023;57:117\u201328. https:\/\/doi.org\/10.5045\/br.2022.2021145.","journal-title":"Blood"},{"key":"1549_CR14","doi-asserted-by":"publisher","first-page":"1048567","DOI":"10.3389\/fimmu.2023.1048567","volume":"14","author":"L Serna","year":"2023","unstructured":"Serna L, Azcoaga P, Brahmachary M, et al. Diffuse large B-cell lymphoma microenvironment displays a predominant macrophage infiltrate marked by a strong inflammatory signature. Front Immunol. 2023;14:1048567. https:\/\/doi.org\/10.3389\/fimmu.2023.1048567.","journal-title":"Front Immunol"},{"key":"1549_CR15","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1182\/blood-2016-10-744292","volume":"129","author":"M Tout","year":"2017","unstructured":"Tout M, Casasnovas O, Meignan M, et al. Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. Blood. 2017;129:2616\u201323.","journal-title":"Blood"},{"key":"1549_CR16","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40262-016-0470-8","volume":"56","author":"M Tout","year":"2017","unstructured":"Tout M, Gagez AL, Lepretre S, et al. Influence of FCGR3A-158V\/F genotype and baseline CD20 antigen count on target-mediated elimination of rituximab in patients with chronic lymphocytic leukemia: a study of FILO group. Clin Pharmacokinet. 2017;56:635\u201347.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"1549_CR17","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1111\/bcp.14102","volume":"85","author":"A Bensalem","year":"2019","unstructured":"Bensalem A, Mulleman D, Thibault G, et al. CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis. Br J Clin Pharmacol. 2019;85(12):2747\u201358. https:\/\/doi.org\/10.1111\/bcp.14102.","journal-title":"Br J Clin Pharmacol"},{"key":"1549_CR18","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/bcp.13270","volume":"83","author":"B Lioger","year":"2017","unstructured":"Lioger B, Edupuganti SR, Mulleman D, et al. Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. Br J Clin Pharmacol. 2017;83:1773\u201381.","journal-title":"Br J Clin Pharmacol"},{"key":"1549_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jim.2007.06.011","volume":"325","author":"H Blasco","year":"2007","unstructured":"Blasco H, Lalmanach G, Godat E, et al. Evaluation of a peptide ELISA for the detection of rituximab in serum. J Immunol Methods. 2007;325:127\u201339.","journal-title":"J Immunol Methods"},{"issue":"9","key":"1549_CR20","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1111\/bcp.13991","volume":"85","author":"D Ternant","year":"2019","unstructured":"Ternant D, Monjanel H, Venel Y, et al. Nonlinear pharmacokinetics of rituximab in non-Hodgkin lymphomas: A pilot study. Br J Clin Pharmacol. 2019;85(9):2002\u201310. https:\/\/doi.org\/10.1111\/bcp.13991.","journal-title":"Br J Clin Pharmacol"},{"key":"1549_CR21","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1182\/blood.V100.6.2087","volume":"100","author":"RJ Hansen","year":"2002","unstructured":"Hansen RJ, Balthasar JP. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood. 2002;100:2087\u201393.","journal-title":"Blood"},{"key":"1549_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/bdd.1997","volume":"37","author":"CM Ng","year":"2016","unstructured":"Ng CM. Incorporation of FcRn-mediated disposition model to describe the population pharmacokinetics of therapeutic monoclonal IgG antibody in clinical patients. Biopharm Drug Dispos. 2016;37:107\u201319.","journal-title":"Biopharm Drug Dispos"},{"key":"1549_CR23","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/psp4.41","volume":"4","author":"P Dua","year":"2015","unstructured":"Dua P, Hawkins E, van der Graaf PH. A tutorial on target-mediated drug disposition (TMDD) models. CPT Pharmacometrics Syst Pharmacol. 2015;4:324\u201337.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1549_CR24","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10928-008-9102-8","volume":"35","author":"L Gibiansky","year":"2008","unstructured":"Gibiansky L, Gibiansky E, Kakkar T, et al. Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn. 2008;35:573\u201391.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1549_CR25","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jconrel.2014.10.003","volume":"196","author":"L Guilleminault","year":"2014","unstructured":"Guilleminault L, Azzopardi N, Arnoult C, et al. Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system. J Control Release. 2014;196:344\u201354.","journal-title":"J Control Release"},{"key":"1549_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10928-014-9349-1","volume":"41","author":"L Fronton","year":"2014","unstructured":"Fronton L, Pilari S, Huisinga W. Monoclonal antibody disposition: a simplified PBPK model and its implications for the derivation and interpretation of classical compartment models. J Pharmacokinet Pharmacodyn. 2014;41:87\u2013107.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"11","key":"1549_CR27","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3390\/pharmaceutics13111821","volume":"13","author":"D Ternant","year":"2021","unstructured":"Ternant D, Le Tilly O, Picon L, et al. Infliximab efficacy may be linked to full TNF-\u03b1 blockade in peripheral compartment-a double central-peripheral target-mediated drug disposition (TMDD) model. Pharmaceutics. 2021;13(11):1821. https:\/\/doi.org\/10.3390\/pharmaceutics13111821.","journal-title":"Pharmaceutics"},{"key":"1549_CR28","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.4049\/jimmunol.0903296","volume":"184","author":"T Suzuki","year":"2010","unstructured":"Suzuki T, Ishii-Watabe A, Tada M, et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol. 2010;184:1968\u201376.","journal-title":"J Immunol"},{"key":"1549_CR29","doi-asserted-by":"publisher","first-page":"2231128","DOI":"10.1080\/1940862.2023.2231128","volume":"15","author":"AR Crowley","year":"2023","unstructured":"Crowley AR, Mehlenbacher MR, Sajadi MM, et al. Evidence of variable human Fc\u03b3 receptor-Fc affinities across differentially-complexed IgG. MAbs. 2023;15:2231128. https:\/\/doi.org\/10.1080\/1940862.2023.2231128.","journal-title":"MAbs"},{"key":"1549_CR30","doi-asserted-by":"publisher","first-page":"928","DOI":"10.4161\/mabs.28744","volume":"6","author":"T Neuber","year":"2014","unstructured":"Neuber T, Frese K, Jaehrling J, et al. Characterization and screening of IgG binding to the neonatal Fc receptor. MAbs. 2014;6:928\u201342. https:\/\/doi.org\/10.4161\/mabs.28744.","journal-title":"MAbs"},{"key":"1549_CR31","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/psp4.12555","volume":"9","author":"L Ngo","year":"2020","unstructured":"Ngo L, Oh J, Kim A, et al. Development of a pharmacokinetic model describing neonatal Fc receptor-mediated recycling of HL2351, a novel hybrid Fc-fused interleukin-1 receptor antagonist, to optimize dosage regimen. CPT Pharmacometrics Syst Pharmacol. 2020;9:584\u201395.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1549_CR32","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1177\/09612033211045049","volume":"30","author":"R Yanis","year":"2021","unstructured":"Yanis R, Bergua C, Christelle B, et al. Neonatal Fc receptor expression in lymphoid and myeloid cells in systemic lupus erythematosus. Lupus. 2021;30:1938\u201345.","journal-title":"Lupus"},{"key":"1549_CR33","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/bcp.12662","volume":"80","author":"S Assouline","year":"2015","unstructured":"Assouline S, Buccheri V, Delmer A, et al. Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia. Br J Clin Pharmacol. 2015;80:1001\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"1549_CR34","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/psp4.12665","volume":"10","author":"E Gibiansky","year":"2021","unstructured":"Gibiansky E, Gibiansky L, Chavanne C, et al. Population pharmacokinetic and exposure-response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia. CPT Pharmacometrics Syst Pharmacol. 2021;10:914\u201327.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1549_CR35","doi-asserted-by":"publisher","first-page":"019","DOI":"10.1007\/s11095-019-2605-8","volume":"36","author":"SM Lavezzi","year":"2019","unstructured":"Lavezzi SM, de Jong J, Neyens M, et al. Systemic exposure of rituximab increased by ibrutinib: pharmacokinetic results and modeling based on the HELIOS trial. Pharm Res. 2019;36:019\u20132605.","journal-title":"Pharm Res"},{"key":"1549_CR36","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1177\/0091270011430506","volume":"52","author":"J Li","year":"2012","unstructured":"Li J, Zhi J, Wenger M, et al. Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. J Clin Pharmacol. 2012;52:1918\u201326.","journal-title":"J Clin Pharmacol"},{"key":"1549_CR37","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1177\/0091270005277075","volume":"45","author":"CM Ng","year":"2005","unstructured":"Ng CM, Bruno R, Combs D, et al. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol. 2005;45:792\u2013801.","journal-title":"J Clin Pharmacol"},{"key":"1549_CR38","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","volume":"128","author":"KD Mason","year":"2007","unstructured":"Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128:1173\u201386. https:\/\/doi.org\/10.1016\/j.cell.2007.01.037.","journal-title":"Cell"},{"key":"1549_CR39","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.3389\/fimmu.2018.02259","volume":"9","author":"DC Castaneda","year":"2018","unstructured":"Castaneda DC, Dhomm\u00e9e C, Baranek T, et al. Lack of FcRn impairs natural killer cell development and functions in the tumor microenvironment. Front Immunol. 2018;9:2259. https:\/\/doi.org\/10.3389\/fimmu.2018.02259.","journal-title":"Front Immunol"},{"key":"1549_CR40","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s40262-023-01270-2","volume":"62","author":"S Lobet","year":"2023","unstructured":"Lobet S, Paintaud G, Azzopardi N, et al. Relationship between cetuximab target-mediated pharmacokinetics and progression-free survival in metastatic colorectal cancer patients. Clin Pharmacokinet. 2023;62:1263\u201374.","journal-title":"Clin Pharmacokinet"},{"key":"1549_CR41","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/bcp.15983","volume":"90","author":"S Lobet","year":"2024","unstructured":"Lobet S, Caulet M, Paintaud G, et al. Confounding mitigation for the exposure-response relationship of bevacizumab in colorectal cancer patients. Br J Clin Pharmacol. 2024;90:976\u201386.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01549-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01549-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01549-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T01:03:53Z","timestamp":1763168633000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01549-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1549"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01549-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"6 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used rituximab pharmacokinetic data belonging to the Lymphoma Study Association (LYSA, France), the French Innovative Leukemia Organization (FILO, France), the Mayo Clinic (Rochester, MN, USA), and Tours University Hospital (Tours, France). The study in patients with DLBCL or follicular lymphoma was funded by GELA and GOELAMS groups and F. Hoffman-La Roche Ltd (Basel, Switzerland). The study in patients with CLL was funded by the FILO Group and Roche SAS (Neuilly, France). Measurements of rituximab serum concentrations in patients with CLL, DLBCL, follicular lymphoma (FL), or RA were carried out via the CePiBAc platform. CePiBAc was co-financed by the EU. Europe is committed to the region Centre with the European Regional Development Fund. CePiBAc was partly supported by the French Higher Education and Research ministry under the program \u2018Investissements d\u2019avenir\u2019 grant agreement: LabEx MAbImprove ANR-10-LABX-53-01.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Theodora Bejan-Angoulvant has no conflicts of interest to declare. She can be added to the lists of authors with no conflict of interest, for instance 'C\u00e9line Desvignes, Theodora Bejan-Angoulvant and Val\u00e9rie Gouilleux-Gruart have no conflicts of interest to declare","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All studies were approved by the local ethics committee, and all patients provided written informed consent. Samples from the registered single-center cohort (University Hospital of Tours, France) with RA were primarily used for therapeutic drug monitoring routine, are part of a declared biological collection (N\u25e6DC2016\u20132739), and conformed with the National Data Information and Freedom Commission. All data sets were anonymized before data analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Patients provided written informed consent, which included consent to participate.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Patients provided written informed consent, which included consent for publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data and material and code are available upon request to the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability:"}},{"value":"Code is available upon request to the corresponding author.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability:"}},{"value":"C\u00e9line Desvignes contributed to materials, participated in data management and reviewed the manuscript. Theodora Bejan-Angoulvant analyzed the data, interpreted the results and reviewed the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}